1. Home
  2. QLGN vs BTOG Comparison

QLGN vs BTOG Comparison

Compare QLGN & BTOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • BTOG
  • Stock Information
  • Founded
  • QLGN 1996
  • BTOG 2018
  • Country
  • QLGN United States
  • BTOG Singapore
  • Employees
  • QLGN N/A
  • BTOG N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • BTOG Finance: Consumer Services
  • Sector
  • QLGN Health Care
  • BTOG Finance
  • Exchange
  • QLGN Nasdaq
  • BTOG Nasdaq
  • Market Cap
  • QLGN 2.4M
  • BTOG 2.0M
  • IPO Year
  • QLGN N/A
  • BTOG 2019
  • Fundamental
  • Price
  • QLGN $3.32
  • BTOG $0.15
  • Analyst Decision
  • QLGN
  • BTOG
  • Analyst Count
  • QLGN 0
  • BTOG 0
  • Target Price
  • QLGN N/A
  • BTOG N/A
  • AVG Volume (30 Days)
  • QLGN 111.5K
  • BTOG 51.6M
  • Earning Date
  • QLGN 04-15-2025
  • BTOG 01-01-0001
  • Dividend Yield
  • QLGN N/A
  • BTOG N/A
  • EPS Growth
  • QLGN N/A
  • BTOG N/A
  • EPS
  • QLGN N/A
  • BTOG N/A
  • Revenue
  • QLGN N/A
  • BTOG $2,888,482.00
  • Revenue This Year
  • QLGN N/A
  • BTOG N/A
  • Revenue Next Year
  • QLGN N/A
  • BTOG N/A
  • P/E Ratio
  • QLGN N/A
  • BTOG N/A
  • Revenue Growth
  • QLGN N/A
  • BTOG N/A
  • 52 Week Low
  • QLGN $2.96
  • BTOG $0.16
  • 52 Week High
  • QLGN $29.45
  • BTOG $5.73
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 44.88
  • BTOG 34.83
  • Support Level
  • QLGN $3.06
  • BTOG $0.25
  • Resistance Level
  • QLGN $3.78
  • BTOG $0.20
  • Average True Range (ATR)
  • QLGN 0.28
  • BTOG 0.02
  • MACD
  • QLGN 0.03
  • BTOG -0.00
  • Stochastic Oscillator
  • QLGN 19.80
  • BTOG 2.57

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About BTOG Bit Origin Limited

Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions.

Share on Social Networks: